Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Clin Cancer Res. 2011 Feb 23;17(7):2024–2034. doi: 10.1158/1078-0432.CCR-10-2567

Fig. 4.

Fig. 4

An activated-MYC signature derived from LTED cells predicts poor outcome following adjuvant tamoxifen therapy. A) The MYC score was applied to cohort LOI164 and stratified by tertile. Kaplan-Meier survival curves were generated and the high tertile was compared to the combined intermediate and low tertiles by the log-rank test. B) MYC score (excluding MYC itself) was compared to MYC mRNA levels in patients from (A) by least squares regression. C-D) Cohorts LOI181 (C) and MDACC298 (D) were analyzed as in (A). E) MYC protein expression was quantified in 47 ER+ early-stage breast tumors (cohort MDACC47). Data were analyzed as in (A).